NPI registry status
Active
2026 NPPES data Specialist NPI 1487716544 MD
Verify on CMS → Samuel Mayeda, MD
Specialist in Orange, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 69,567 in Specialist, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
5K
Medicare Part D claims · 216 beneficiaries · Specialist avg: 2K
Generic prescribing
72%
generic claims · 26% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
65.6/100
▼ 18 pts below national avg 83.5 · Mid-tier
Industry payments
$964.61
53 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Samuel Mayeda, MD reported a CMS MIPS final score of 65.6/100 - below the 83.5 national average - and filed 4,857 Medicare Part D claims in 2024.
- 65.6/100
- MIPS score · -18 vs avg
- 5K
- Part D claims, 2024
- 72%
- generic prescribing
- $964.61
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Samuel Mayeda, MD
Federal records show an active NPI with both Medicare prescribing volume and a measured CMS quality score — objective registry data, not patient reviews.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1487716544), first enumerated 12/15/2006.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 4,857 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
CMS quality reporting (MIPS)
Reported a CMS MIPS final score of 65.6/100 in the Quality Payment Program — a federal quality measure, not a patient review.
Source: CMS Quality Payment Program
- Reported
Industry payment transparency
$964.61 in reported industry payments (53 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- State context
State board disciplinary context
California statewide board action statistics are published annually — these figures describe aggregate state activity, not Samuel Mayeda, MD's individual license status. Verify directly with the state medical board.
Source: MBC annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1487716544 · Specialist
NPI-10 · ENUM-LEGACY · TAX-MEGA · MIPS-LOW · RX-MID · BOOK-MID · PHOTO-FINISH
- NPI-10 1487716544
- ENUM-LEGACY 2006
- TAX-MEGA 70K Specialist
- MIPS-LOW 65.6/100
- RX-MID 4,857
- BOOK-MID 6,640 in California
- PHOTO-FINISH James Ogrodowski · ±0.1
MIPS final-score neighbourhood
Same-specialty nationwide peers by CMS final score, not geographic proximity
- Ramez Awwad · lo…
Ramez Awwad
65.4 MIPS pts
- Robert Cadoff · …
Robert Cadoff
65.5 MIPS pts
- Steven Humphreys…
Steven Humphreys
65.5 MIPS pts
- Mayeda · this pr…
Mayeda · this provider
65.6 MIPS pts
- James Ogrodowski…
James Ogrodowski
65.7 MIPS pts
What this shows Nearest measured MIPS peers for this NUCC specialty (2023 performance year).
Samuel Mayeda, MD's MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
66 ≥ 7th percentile 7% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Samuel Mayeda, MD sits
This provider among specialist peers
Across the 4,261 specialist providers who report both Medicare Part D prescribing and a MIPS quality score, Samuel Mayeda, MD writes more Part D claims than 89% of them and scores higher on MIPS quality than 20% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one specialist peer from a representative sample of 60; the gold marker is Samuel Mayeda, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
What does the federal data show about Samuel Mayeda, MD?
Below national averagePrimary specialty
Specialist
Medicare Part D claims
4,857 219% vs specialty avg
MIPS final score
65.6/100 17.9 pts vs avg
Specialty distribution in California
How Specialist compares to other specialties among California providers
Medicare quality performance, MIPS
Samuel Mayeda, MD's 2023 MIPS final score plotted against the Specialist national average
- MIPS Final Score
- 65.6/100
- vs 83.5 national avg · 2023 performance year
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1487716544 |
|---|---|
| Specialty | Specialist |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 12/15/2006 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
65.5727
Final Score
Measured-score avg: 83.5
74.0688
Quality
36.1735
Cost
70
Promoting Interoperability
Reporting: Individual
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Samuel Mayeda, MD. Source: openpaymentsdata.cms.gov.
Total received
$965
Largest payer
Novartis Pharmaceuticals Corporation
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Samuel Mayeda, MD. To verify Samuel Mayeda, MD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
Samuel Mayeda, MD - brand share 26.0%
Specialist average
26% brand-name claims vs 72% generic, on 4,857 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
4,857
Total Claims
$4.5M
Total Drug Cost
216
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 11,738.633
- Total Day Supply
- 343,545
- Brand vs Generic
- 26% brand / 72% generic
- Brand Drug Cost
- $4.4M
- Generic Drug Cost
- $120K
- Opioid Claims
- 58 (1.2% rate)
- Antibiotic Claims
- 169
Patient Demographics
- Average Patient Age
- 77.6 years
- Avg HCC Risk Score
- 1.42
- Gender Split
- 56% female / 44% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Samuel Mayeda, MD prescribes most
Top Medicare Part D drugs by claim count, 2024
- Levothyroxine Sodium
Levothyroxine Sodium
323 claims
- Ezetimibe
Ezetimibe
234 claims
- Rosuvastatin Calcium
Rosuvastatin Calcium
183 claims
- Amlodipine Besylate
Amlodipine Besylate
162 claims
- Telmisartan 128
Telmisartan
128 claims
- Atorvastatin Calcium 125
Atorvastatin Calcium
125 claims
- Metformin Hcl 125
Metformin Hcl
125 claims
- Ozempic 125
Ozempic
125 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 323 |
| Ezetimibe | 234 |
| Rosuvastatin Calcium | 183 |
| Amlodipine Besylate | 162 |
| Telmisartan | 128 |
| Atorvastatin Calcium | 125 |
| Metformin Hcl | 125 |
| Ozempic Semaglutide | 125 |
| Synthroid Levothyroxine Sodium | 124 |
| Mounjaro Tirzepatide | 87 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Specialist Overview
How Samuel Mayeda, MD fits within the Specialist landscape nationally.
69,567
Specialist Providers in US
55
States with Specialist
1,524
Avg Claims per Provider
Samuel Mayeda, MD's 4,857 claims are above the specialty average of 1,524.
Nationwide Specialist peers with similar MIPS or enrollment year
Two federal-record peer sets for Mayeda, both outside California so the neighborhoods are not geographic containment.
Similar MIPS final score
Nearest same-specialty clinicians by CMS MIPS final score (65.6 here).
Same NPPES enumeration year (2006)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Specialist Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Mayeda.
One of 6,640 Specialist providers enrolled in California, 5 are shown here.
Adrienne Abad Santos
San Francisco, CA
Dr. Brenda Abarca
MD
Torrance, CA
Fatemeh Abbasi
PT
Van Nuys, CA
Dr. Erlinda Abcede
M.D.
Cudahy, CA
Dr. Maher Abdallah
M.D.
Palm Springs, CA
Compare Specialist nationally: see state-by-state distribution →
Frequently Asked Questions
What is Samuel Mayeda, MD's specialty? ▼
Samuel Mayeda, MD specializes in Specialist and practices in Orange, California. Credentials: MD.
How much does Samuel Mayeda, MD prescribe under Medicare Part D? ▼
In 2024, Samuel Mayeda, MD wrote 4,857 Medicare Part D claims totaling $4.5M in drug costs for 216 beneficiaries.
What is Samuel Mayeda, MD's Medicare quality score? ▼
Samuel Mayeda, MD has a CMS MIPS Final Score of 65.6/100 (Quality: 74.1, Cost: 36.2). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Samuel Mayeda, MD located? ▼
Samuel Mayeda, MD is located at 1140 W LA VETA AVE STE 420, Orange, CA, 92868. Phone: (714) 285-1904.
What is Samuel Mayeda, MD's NPI number? ▼
Samuel Mayeda, MD's National Provider Identifier (NPI) is 1487716544, issued on 12/15/2006.
Does Samuel Mayeda, MD prescribe more brand-name or generic drugs? ▼
Samuel Mayeda, MD's prescribing is 26% brand-name and 72% generic drugs by claim count, with $4.4M in brand drug costs.
Does Samuel Mayeda, MD prescribe opioids? ▼
Yes, Samuel Mayeda, MD had 58 opioid claims in 2024 with an opioid prescribing rate of 1.2%.
How many Specialist providers are there in the US? ▼
There are 69,567 Specialist providers across 55 states in the US. The average Specialist provider writes 1,524 Medicare Part D claims per year.
What drugs does Samuel Mayeda, MD prescribe most often? ▼
Based on 2024 Medicare Part D data, Samuel Mayeda, MD's most frequently prescribed drugs include Levothyroxine Sodium, Ezetimibe, Rosuvastatin Calcium. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Samuel Mayeda, MD accept Medicare? ▼
Samuel Mayeda, MD appears in CMS Medicare data with 4,857 Part D claims and 216 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Samuel Mayeda, MD's credentials? ▼
Samuel Mayeda, MD's NPI is 1487716544 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.